Drug intelligence / Profile preview

ZYY-742

Development stage: Unknown
Lead developer: Longfengtang
Administration: Topical

Overview

**ZYY-742** is an investigational topical traditional Chinese medicine gel being developed by Yangtze River Pharmaceutical Group affiliates for treatment of anti-EGFR targeted therapy-associated papulopustular rash. Its active chemical or botanical composition and molecular targets have not been publicly disclosed. A randomized, double-blind, placebo-controlled, multicenter Phase 2 study is registered in China for rash associated with EGFR-targeted anticancer therapy. ([synapse.zhihuiya.com](https://synapse.zhihuiya.com/drug/2a850f4b92044c0e8483aad20cab5eba))

Other names: ZYY-742 gelZYY742 gelZYY 742 gel

Beyond the preview

Go deeper on ZYY-742.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ZYY-742.

Explore the full profile